Company / FCF Margin
Zenas BioPharma, Inc. FCF Margin History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-1723.5%
FY2025
5-year range
-1723.5% / -61.1%
FY2024-FY2025
Trend
-2721.3%
vs FY2024
Sector context
#125 of 134
Health Care
What the data says
Among 134 Health Care companies, Zenas BioPharma, Inc. is in the bottom 7% for fcf margin.
Based on SEC 10-K filings.
-1723.5% in FY2025.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 134This company -1723.5% Sector average -637.8%
▼
-170.2% below sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 2721.3% year-over-year.
- Currently 1085.7pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1723.5% | -2721.3% |
| FY2024 | -61.1% | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026